The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
Robyn M. Scherber(Blueprint Medicines (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Ayalew Tefferi(Mayo Clinic), Deepti Radia(St Thomas' Hospital), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Jan Samuelsson(Karolinska University Hospital), Peter Johansson(Linköping University), Björn Andréasson(NU Hospital Group), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Tiziano Barbui(University of Bergamo), Maria L Ferarri(Centre Hospitalier Universitaire de Grenoble), Giovanni Barosi(Policlinico San Matteo Fondazione), Francesco Passamonti(University of Milan), Amylou C. Dueck(Mayo Clinic in Arizona), Gunnar Birgegård(Uppsala University Hospital)
Cited by 340
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k